secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001558370-23-018578
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg
--------------------------------------------------------------------------------

- Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.
- Cash $59.8M (Sep 30) vs $120.4M (Dec 31); runway into Q2 2024.
- XTX202 Phase 1/2: 50% disease control rate at ≥2.8 mg/kg; no vascular leak syndrome.
- XTX101: >70% tumor activation in biopsies; clinical trial collaboration with Roche to start combo with atezolizumab in Q4 2023.
- XTX301 preliminary Phase 1 safety data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/xlo-20231109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer